Antiviral Activity and Pharmacokinetics of Liposome-Encapsulated Phosphonoformate in Rauscher Murine Leukemia Virus-Infected Mice

References

• Stella V. J., Himmelstein K. J. Prodrugs and site-specific drug delivery. J. Med. Chem. 1980; 23: 1275
   PubMed Web of Science ®Google Scholar
• Hunt C. A., MacGregor R. D., Siegel R. A. Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharm. Res. 1986; 3: 333
   PubMed Web of Science ®Google Scholar
• Chu C. J., Szoka F. C. Increased efficacy of phosphonoformate and phosphonoacetate inhibition of Herpes simplex virus type 2 replication by encapsulation in liposomes. Antimicrob. Agents Chemother. 1988; 32: 858
   PubMed Web of Science ®Google Scholar
• Oberg B. Antiviral effects of phosphonoformate. Pharmacol. Ther. 1989; 40: 213
   PubMed Web of Science ®Google Scholar
• Ringden O., Lonnqvist B., Paulin T., Ahlmen J., Klintmalm G., Wahren B., Lernestedt J.-O. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J. Antimicrob. Chemother. 1986; 17: 373
   PubMed Web of Science ®Google Scholar
• Rauscher F. J. A virus-induced disease of mice characterized by erythrocytopoiesis and lymphoid leukemia. J. Natl. Cancer Inst. 1962; 29: 515
   PubMedGoogle Scholar
• Ruprecht R. M. Murine models for antiretroviral therapy. Intervirology 1989; 30: 2
   PubMed Web of Science ®Google Scholar
• Knyszynski A., Danon D. The role of macrophages in defense against the development of Rauscher virus leukemia. J. Reticuloendothel. Soc. 1977; 22: 341
   PubMedGoogle Scholar
• Buchnma V. M., Radzichovskaya G., Svet-Moldavsky G. J., Kozlova M. D., Mikaelian S. E., Levin V. J. Loading of the reticuloendothelial system: effect on the induction, development and chemotherapy of Rauscher virus leukemia. Biomedicine 1973; 19: 335
   PubMedGoogle Scholar
• Abra R. H., Schreier H., Szoka F. C. The use of a new radioactiveiodine labeled lipid marker to follow in vivo disposition of liposomes: comparison with an encapsulated aqueous marker. Res. Commun. Pathol. Pharmacol. 1982; 37: 199
   PubMedGoogle Scholar
• Gawell L. One pot procedure for the preparation of 14C-labeled trisodium phosphonoformate hexahydrate (foscarnet). J. Label. Comp. Radiopharm. 1983; XX: 813
   Google Scholar
• Scheinberg D. A., Strand M. Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer Res. 1982; 42: 44
   PubMed Web of Science ®Google Scholar
• Szoka F. C., Olson F., Heath T., Vail W., Mayhew E., Papahajopoulos D. Preparation of unilamellar liposomes of intermediate size (0.1–0.2μm) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim. Biophys. Acta 1980; 601: 559
   PubMed Web of Science ®Google Scholar
• Pluznik D. H., Sachs L. Quantitation of a murine leukemia virus with a spleen colony assay. J. Nat. Cancer Inst. 1964; 33: 535
   PubMedGoogle Scholar
• Chirigos M. A. Studies with the murine leukemogenic Rauscher virus. III. An in vivo assay for antiviral agents. Cancer Res. 1964; 24: 1035
   PubMed Web of Science ®Google Scholar
• Szoka F. C. The cellular availability of liposome-encapsulated agents: consequences for drug delivery. Application of Liposomes Medical, K. Yagi. Japan Scientific Press, Tokyo 1986; 21
   Google Scholar
• Morse B., Giuliani D., Fredrickson T. N., LoBue J. Erythrokinetics and ferrokinetics of a viral-induced murine erythroblastosis. Blood 1978; 51: 623
   PubMed Web of Science ®Google Scholar
• Abraham I., Hilchie J. C., Mezei M. Pharmacokinetic profile of intravenous liposomal triamcinolone acetonide in the rabbit. J. Pharm. Sci. 1983; 72: 1412
   PubMed Web of Science ®Google Scholar
• Rahman A., Carmichael D., Harris M., Roh J. K. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 1986; 46: 2295
   PubMed Web of Science ®Google Scholar
• Pharmacokinetics, M. Gibaldi, D. Perrier. Marcel Dekker Inc., New York 1982
   Google Scholar
• De Both N. J., Vermey M., Van Griensven L. J.L.D. The effect of Rauscher murine leukemia virus infection on the hemapoietic system of BALB/c mice. Exp. Hematol. 1978; 6: 515
   PubMed Web of Science ®Google Scholar
• LoBue J. Viral-associated alterations in hematopoiesis in the mouse. Blood Cells 1984; 10: 211
   PubMedGoogle Scholar
• Ranade V. V. Drug delivery system. 1. Site specific drug delivery using liposomes as carriers. J. Clin. Pharmacol. 1989; 29: 685
   PubMed Web of Science ®Google Scholar
• Hirano K., Hunt C. A. Lymphatic transport of liposome-encapsulated agents: Effects of liposomes size following intraperitoneal administration. J. Pharmacol. Sci. 1985; 74: 915
   PubMed Web of Science ®Google Scholar
• Parker R. J., Priester E. R., Sieber S. M. Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine β-D-arabinofuranoside following intraperitoneal administration to rats. Drug. Metab. Dispos. 1982; 10: 40
   PubMed Web of Science ®Google Scholar
• Bosworth M. E., Hunt C. A. Liposome disposition in vivo II: dose dependency. J. Pharm. Sci. 1982; 71: 100
   PubMed Web of Science ®Google Scholar
• Chu C.-J. Increased efficiency of inhibition of Herpes simplex virus type 2 replication by liposome encapsulated phosphonoformate and phosphonoacetate. Enhanced Cytoplasmic Delivery via Liposomes. Ph.D. thesis, University of California, San Francisco 1990; 74
   Google Scholar
• Mayhew E., Rustum Y. M., Szoka F. C. Therapeutic efficacy of cytosine arabinoside trapped in liposomes. Targeting of Drugs, G. Gregoriadis, J. Senior, A. Trouet. Plenum Press, New York 1982; 249
   Google Scholar
• Gabizon A., Goren D., Fuks Z., Barenholz Y., Dagan A., Meshorer A. Enhancement of adriamycin delivery to liver metastatic cells with increased tumorcidal effect using liposomes as drug carriers. Cancer Res. 1983; 43: 4730
   PubMed Web of Science ®Google Scholar
• Storm G., Steerenberg P. A., Emmen F., Van Borssum Waalkes M., Crommelin D. J.A. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim. Biophys. Acta 1988; 965: 136
   PubMed Web of Science ®Google Scholar
• Crowe S., Mills J., McGrath M. S. Quantitative immunocytofluoro-graphic analysis of CD4 surface antigen expression and HIV infection of human peripheral blood monocytes/macrophages. AIDS Res. Hum. Retroviruses 1987; 3: 46
   Web of Science ®Google Scholar
• Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. The role of mononuclear phagocytes in HTLV-III infection. Science 1986; 233: 215
   PubMed Web of Science ®Google Scholar
• Sandstrom E. G., Kaplan J., Byington R. E., Hirsch M. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 1985; 1: 1480
   PubMed Web of Science ®Google Scholar
• Gaub J., Pedersen G., Poulson A-G., Mathiesen L. R., Ulrich K., Lindhardt B. O., Faber V., Gerstoft J., Hoffmann B., Lernestedt J.-O., Nielsen C. M., Nielsen J. E., Platz P. The effect of Foscarnet (phosphono-formate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1987; 1: 27
   PubMed Web of Science ®Google Scholar